Literature DB >> 16413916

Development of effective vaccines against pandemic influenza.

Kanta Subbarao1, Brian R Murphy, Anthony S Fauci.   

Abstract

A key strategy to protect humans against an influenza pandemic is the development of an effective vaccine. However, the development of effective pandemic vaccines poses both practical and immunological challenges.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16413916     DOI： 10.1016/j.immuni.2005.12.005

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  69 in total

Review 1.  Influenza: the once and future pandemic.

Authors:  Jeffery K Taubenberger; David M Morens
Journal:  Public Health Rep       Date:  2010-04       Impact factor: 2.792

2.  B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms.

Authors:  Javier Rangel-Moreno; Damian M Carragher; Ravi S Misra; Kim Kusser; Louise Hartson; Amy Moquin; Frances E Lund; Troy D Randall
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

Review 3.  The threat of avian influenza A (H5N1). Part IV: Development of vaccines.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-06-01       Impact factor: 3.402

4.  Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness.

Authors:  David M Morens; Jeffery K Taubenberger; Anthony S Fauci
Journal:  J Infect Dis       Date:  2008-10-01       Impact factor: 5.226

5.  A primer on strategies for prevention and control of seasonal and pandemic influenza.

Authors:  Scott Santibañez; Anthony E Fiore; Toby L Merlin; Stephen Redd
Journal:  Am J Public Health       Date:  2009-10       Impact factor: 9.308

6.  Toward a method for tracking virus evolutionary trajectory applied to the pandemic H1N1 2009 influenza virus.

Authors:  R Burke Squires; Brett E Pickett; Sajal Das; Richard H Scheuermann
Journal:  Infect Genet Evol       Date:  2014-07-24       Impact factor: 3.342

7.  5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.

Authors:  Alain Beck; Janice M Reichert; Thierry Wurch
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

8.  Two distinct conformations of a rinderpest virus epitope presented by bovine major histocompatibility complex class I N*01801: a host strategy to present featured peptides.

Authors:  Xin Li; Jun Liu; Jianxun Qi; Feng Gao; Qirun Li; Xiaoying Li; Nianzhi Zhang; Chun Xia; George F Gao
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

9.  M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection.

Authors:  Wenqian Tao; Harvinder S Gill
Journal:  Vaccine       Date:  2015-04-02       Impact factor: 3.641

10.  Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins.

Authors:  Katherine A Richards; Francisco A Chaves; Shabnam Alam; Andrea J Sant
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.